2024
Re-Evaluating the Transplant Glomerulopathy Lesion—Beyond Donor-Specific Antibodies
Chutani A, Guevara-Pineda D, Lerner G, Menon M. Re-Evaluating the Transplant Glomerulopathy Lesion—Beyond Donor-Specific Antibodies. Transplant International 2024, 37: 13365. DOI: 10.3389/ti.2024.13365.Peer-Reviewed Original ResearchTransplant glomerulopathyLonger-term graft survivalCell-mediated immune mechanismsChronic allograft damageNon-HLA antibodiesDonor-specific antibodiesAnti-HLA alloantibodiesChronic allograft dysfunctionPathogenesis of transplant glomerulopathyPost-transplant yearComplement-mediated injuryShort-term outcomesAllograft dysfunctionAllograft damageGraft lossGraft survivalRenal transplantationEtiological diagnosisPodocyte stressHistological manifestationsImmune mechanismsMorphological lesionsGlomerulopathyTransplantationReview article
2022
Donor–Recipient Non-HLA Variants, Mismatches and Renal Allograft Outcomes: Evolving Paradigms
Jethwani P, Rao A, Bow L, Menon MC. Donor–Recipient Non-HLA Variants, Mismatches and Renal Allograft Outcomes: Evolving Paradigms. Frontiers In Immunology 2022, 13: 822353. PMID: 35432337, PMCID: PMC9012490, DOI: 10.3389/fimmu.2022.822353.Peer-Reviewed Original ResearchConceptsAllograft outcomesImportant recent dataRenal allograft outcomeAcute allograft rejectionKidney allograft outcomesDonor-recipient mismatchRecipient's immune systemNatural history studiesNon-HLA lociMajority of casesOrgan allocation processPolymorphic HLA genesAcute rejectionAllograft longevityAllograft lossMaintenance immunosuppressionTransplant outcomesAllograft rejectionImmune mechanismsPatient deathRecipient pairsDonor organsHLA variantsImmune systemOvert evidence